Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors.
Journal
Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
medline:
7
10
2024
pubmed:
7
10
2024
entrez:
7
10
2024
Statut:
aheadofprint
Résumé
Akathisia is an underestimated but disturbing extrapyramidal side effect of antidepressants, which could reduce treatment compliance in mood disorders. This study aimed to investigate the frequency and risk factors in patients treated with selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors (SSRI/SNRI). In addition, we assessed the impact of akathisia on the quality of life (QoL). Patients were aged between 18 and 75 years, receiving an SSRI/SNRI for 4-8 weeks, and were diagnosed with anxiety, depression, or obsessive-compulsive disorder. The Barnes Akathisia Rating Scale was used to assess the severity of the akathisia. QoL was evaluated using the Short Form 36 (SF-36) questionnaire. Akathisia was observed in 25% (50/198) of patients. Smokers and younger patients were more frequent among patients with akathisia. Physical functioning, physical role, vitality, and mental health domains of the SF-36 were reduced in the presence of akathisia. In conclusion, our results suggest that akathisia is not a rare side effect of SSRI/SNRI in patients with mood disorders, especially in smokers and younger patients. In addition, akathisia may reduce treatment compliance owing to a reduction in QoL. Further investigations are needed to confirm the risk factors, frequency, and consequences of treatment compliance for SSRI/SNRI-induced akathisia in patients with mood disorders.
Identifiants
pubmed: 39374042
doi: 10.1097/FBP.0000000000000797
pii: 00008877-990000000-00102
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Adler LA, Angrist BM (1995). Paroxetine and akathisia. Biol Psychiatry 37:336–337.
Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS (1996). Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 37:122–124.
Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676.
Bayram E, Çotur Levent H, Tezcan S, Kuzu M, Akbostanci MC (2017). Reliability and validity of the Turkish version of the Barnes Akathisia Rating Scale. Turkish J Neurol 23:56–59.
Bonnet-Brilhault F, Thibaut F, Leprieur A, Petit M (1998). A case of paroxetine-induced akathisia and a review of SSRI-induced akathisia. Eur Psychiatry 13:109–111.
Caley CF (1997). Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 31:1481–1489.
Cetin Erdem H, Kara H, Ozcelik O, Donmez L, Eryilmaz M, Ozbey G (2023). Frequency, risk factors, and impacts on quality of life of the restless legs syndrome and side effects among antidepressant users in a tertiary hospital: an observational cross-sectional study. Int Clin Psychopharmacol 38:209–215.
Cheng HM, Park JH, Hernstadt D (2013). Akathisia: a life-threatening side effect of a common medication. BMJ Case Rep 2013:bcr2012007713.
Demyttenaere K, Detraux J, Racagni G, Vansteelandt K (2019). Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis. CNS Drugs 33:549–566.
Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, et al. (2018). Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement. World J Biol Psychiatry 19:330–348.
Duma SR, Fung VS (2019). Drug-induced movement disorders. Aust Prescr 42:56–61.
Gerber PE, Lynd LD (1998). Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 32:692–698.
Grover S, Valaparla VL (2014). Venlafaxine induced akathisia: a case report. Indian J Pharmacol 46:660–661.
Guo MY, Etminan M, Procyshyn RM, Kim DD, Samii A, Kezouh A, Carleton BC (2018). Association of antidepressant use with drug-related extrapyramidal symptoms: a pharmacoepidemiological study. J Clin Psychopharmacol 38:349–356.
Han C, Wang SM, Kwak KP, Won WY, Lee H, Chang CM, et al. (2015). Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res 66-67:84–94.
Hansen L (2001). A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol 16:495–505.
Hawthorne JM, Caley CF (2015). Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother 49:1136–1152.
Hsu JH, Mulsant BH, Lenze EJ, Sanches M, Karp JF, Reynolds CF, Blumberger DM (2018). Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. J Clin Psychiatry 79:17m–11764.
Kim JH, Byun HJ (2007). Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. J Clin Pharm Ther 32:461–467.
Kocyigit H, Gulseren S, Erol A, Hizli N, Memis A (2003). The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Clin Rheumatol 22:18–23.
Koliscak LP, Makela EH (2009). Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc 49:e28–e38.
Lai CH (2013). Venlafaxine-related akathisia side-effects and management in a depressed patient. Psychiatry Clin Neurosci 67:127–128.
Lambert MT, Trutia C, Petty F (1998). Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 22:741–748.
Lane RM (1998). SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol12:192–214.
Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. (2015). Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet 386:2404–2412.
Leo RJ (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449–454.
Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA (2015). The clinical challenges of akathisia. CNS Spectr 20(20 Suppl 1):1–14; quiz 15.
Luft MJ, Lamy M, DelBello MP, McNamara RK, Strawn JR (2018). Antidepressant-induced activation in children and adolescents: risk, recognition and management. Curr Probl Pediatr Adolesc Health Care 48:50–62.
Maddux RE, Delrahim KK, Rapaport MH (2003). Quality of life in geriatric patients with mood and anxiety disorders. CNS Spectr 8:35–47.
Madhusoodanan S, Alexeenko L, Sanders R, Brenner R (2010). Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 22:148–156.
McHorney CA, Ware JE, Raczek AE (1993). The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263.
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, et al.; and the VAST-D Investigators (2017). Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA 318:132–145.
Olivera AA (1996). A case of paroxetine-induced akathisia. Biol Psychiatry 39:910.
Ozbey G, Celikel FC, Cumurcu BE, Kan D, Yucel B, Hasbek E, et al. (2017). Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder. Nord J Psychiatry 71:230–237.
Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A (2019). Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 15:1249–1258.
Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH (2020). Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry 20:308.
Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, Nelson JC (2014). Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. J Affect Disord 162:20–25.
Van Putten T (1975). The many faces of akathisia. Compr Psychiatry 16:43–47.